Strategic Alliance SomaLogic has become an Illumina company, expanding its reach and credibility in genomics alongside proteomics. This presents cross-sell opportunities to Illumina’s customer base and access to larger pharma and academic accounts seeking integrated genomics-proteomics insights.

High Plex Platform Recent launches offer high-plex proteomics with thousands of protein measurements, enabling more comprehensive biomarker panels. Target customers in translational medicine, oncology, and neurology who require scalable, deep proteomic data to inform studies and companion diagnostics.

Enterprise Partnerships Active collaborations with Novo Nordisk and DNA Link indicate a pattern of partnering with pharma and regional innovators to expand proteomics applications. Leverage these partnerships to approach similar pharma companies and regional healthcare tech firms seeking precision medicine data services.

Global Grants & Access Industry initiatives like the Dubai proteomics grant competition signal demand for proteomics capabilities in new markets. BD opportunities exist to offer SomaScan services via grant programs, regional collaborations, and sponsored research to universities and biotech clusters.

Financial Scale Strong funding trajectory with a substantial funding amount and mid-market revenue position suggests capacity for large pilot projects and long-term contracts. Propose multi-year engagements, data integration services, and scalable deployment to pharmaceutical manufacturers and contract research organizations.